Enanta Pharmaceuticals | ENTA - مصاريف البيع والإدارة





مصاريف البيع والإدارة تغيير تاريخ
AbbVie USD 3.84B 205M 2026-09
Amgen USD 1.68B 40M 2026-09
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 46.63M 4.88M 2026-06
AstraZeneca USD 4.07B 1.73B 2026-09
BioCryst Pharmaceuticals USD 63.98M 31.8M 2026-06
Biogen USD 752M 42.3M 2026-09
Bristol-Myers Squibb USD 1.7B 127M 2026-09
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Gilead Sciences USD 1.52B 70M 2026-06
GlaxoSmithKline GBP 2.16B 39M 2026-09
Halozyme Therapeutics USD 58.24M 1.24M 2026-09
Heron Therapeutics USD 23.74M 605K 2025-12
Immunic USD 3.45M 451K 2025-12
Incyte USD 364.27M 12.54M 2026-09
Insmed USD 253.03M 5.56M 2026-09
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
J&J USD 6.25B 168M 2026-09
Karyopharm Therapeutics USD 10.42M 861K 2026-03
Ligand Pharmaceuticals USD 72.62M 43.49M 2026-09
Merck USD 2.86B 25M 2026-09
Neurocrine Biosciences USD 366.3M 16.8M 2026-09
Novartis USD 3.08B 163M 2026-09
Novavax USD 25.53M 1.34M 2025-12
Pfizer USD 3.28B 132M 2026-09
PTC Therapeutics USD 80.63M 6.74M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sarepta Therapeutics USD 118.61M 11.01M 2026-09
Vertex Pharmaceuticals USD 556.3M 25.9M 2026-09